姜安雅,颜华仙,赵通武

• 1:重庆市黔江中心医院

摘要(Abstract)：

目的 观察自拟凉血解毒汤联合连续性肾脏替代疗法对脓毒症急性肾损伤（SAKI）患者炎症因子及胱抑素的影响。方法 选取SAKI患者60例，随机分为联合组与对照组各30例。两组均予以脓毒症常规治疗，包括积极治疗原发病、抗感染、机械通气、纠正电解质等。对照组予以CRRT治疗，联合组在对照组基础上增用自拟凉血解毒汤。比较两组治疗前后肾功能血清指标[尿素氮（BUN）、肌酐（SCr）、胱抑素C(Cys C)]、炎症指标[超敏C反应蛋白（hs-CRP）、肿瘤坏死因子-α(TNF-α)及白细胞介素-6(IL-6)]及凝血功能指标[凝血酶原时间（PT）、纤维蛋白原（FIB）、活化部分凝血活酶时间（APTT）]，记录两组急性生理与慢性健康状况评分（APACHEⅡ）与氧合指数。结果 联合组治疗后BUN、SCr、Cys C水平显著低于对照组（P <0.05）；联合组治疗后hs-CRP、TNF-α、IL-6水平显著低于对照组（P <0.05）；联合组治疗后PT、活化部分凝血活酶时间分显著低于对照组，FIB水平显著高于对照组（P <0.05）；联合组治疗后APACHEⅡ评分显著低于对照组，氧合指数显著高于对照组（P <0.05）。结论 自拟凉血解毒汤联合CRRT治疗SAKI能够患者的肾功能，抑制炎症反应，改善凝血功能和预后，提高氧合指数。

关键词(KeyWords)： 脓毒症;急性肾损伤;自拟凉血解毒汤;连续性肾脏替代疗法;炎症因子;胱抑素C

Abstract:

Keywords:

基金项目(Foundation):

作者(Author): 姜安雅,颜华仙,赵通武

参考文献(References)：

• [1] Dai X,Zeng Z,Fu C,et al. Diagnostic value of neutrophil gelatinase-associated lipocalin,cystatin C,and soluble triggering receptor expressed on myeloid cells-1 in critically ill patients with sepsis-associated acute kidney injury[J]. Crit Care,2015,19(1):223.
• [2] Gomez H,Ince C,De Backer D,et al. A unified theory of sepsis-induced acute kidney injury:inflammation,microcirculatory dysfunction,bioenergetics,and the tubular cell adaptation to injury[J]. Shock,2014,41(1):3-11.
• [3] Wen Y,Jiang L,Xu Y,et al. China critical care clinical trial group(CCCCTG). Prevalence,risk factors,clinical course,and outcome of acute kidney injury in Chinese intensive care units:a prospective cohort study[J]. Chin Med J(Engl),2013,126(23):4409-4416.
• [4]厉兆春，张旭，刘瑞清.参芪地黄汤治疗脓毒症并发急性肾损伤疗效观察及对尿蛋白的影响[J].山东中医杂志，2019,38(5):439-443.
• [5]狄浩然，卢幼然，吴彦青，等.脓毒症急性肾损伤的发病机制和中医治疗[J].世界中医药，2018,13(8):2079-2083,2089.
• [6]黄瑞峰，唐奇，吕波.保肾排毒汤灌肠治疗脓毒症急性肾损伤临床观察[J].河北中医，2019,41(2):230-233.
• [7] Shankar-Hari M,Phillips GS,Levy ML,et al. Sepsis definitions task force. Developing a new definition and assessing new clinical criteria for septic shock:For the third international consensus definitions for sepsis and septic shock(Sepsis-3)[J]. JAMA,2016,315(8):775-787.
• [8] Khwaja A. KDIGO clinical practice guidelines for acute kidney injury[J]. Nephron Clin Pract,2012,120(4):179-184.
• [9]中华医学会急诊医学分会危重病专家委员会.脓毒症的定义、诊断标准、中医证候诊断要点及说明（草案）[J].中华急诊医学杂志，2007,16(8):797-798.
• [10] Zeng X,McMahon GM,Brunelli SM,et al. Incidence,outcomes,and comparisons across definitions of AKI in hospitalized individuals[J]. Clin J Am Soc Nephrol,2014,9(1):12-20.
• [11] Suh SH,Kim CS,Choi JS,et al. Acute kidney injury in patients with sepsis and septic shock:risk factors and clinical outcomes[J]. Yonsei Med J,2013,54(4):965-972.
• [12]王峰.脓毒症患者治疗中CRRT的应用现状[J].吉林医学，2019,40(12):2886-2888.
• [13]杨婷婷，周瑞祥，姚慧，等.连续性肾脏替代治疗时机选择对脓毒症急性肾损伤患者预后的影响[J].现代仪器与医疗，2019,25(5):11-15.
• [14]刘名胜，邢柏.脓毒症性与非脓毒症性急性肾损伤行CRRT治疗患者临床特征及预后影响因素对比分析[J].山东医药，2020,60(14):60-64.
• [15]王树英.血必净联合连续肾脏替代治疗对外科术后脓毒症患者炎性因子及凝血功能的影响[J].中国中西医结合外科杂志，2020,26(2):282-286.
• [16]刘洪斌，吴咸中，李东华，等.清热解毒方对脓毒症大鼠的治疗作用[J].中国中西医结合外科杂志，2008,14(6):580-584.
• [17] Bang JY,Kim SO,Kim SG,et al. Cystatin-C is associated with partial recovery of kidney function and progression to chronic kidney disease in living kidney donors:Observational study[J]. Medicine(Baltimore),2017,96(5):e6037.
• [19] Wang M,Zhang L,Yue R,et al. Significance of cystatin C for early diagnosis of contrast-induced nephropathy in patients undergoing coronary angiography[J]. Med Sci Monit,2016,22:2956-2961.
• [19] Fenhammar J,Rundgren M,Forestier J,et al. Toll-like receptor 4 inhibitor TAK-242 attenuates acute kidney injury in endotoxemic sheep[J]. Anesthesiology,2011,114(5):1130-1137.